Organization
Calvary Mater Newcastle
7 abstracts
Abstract
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.Org: Dana-Farber Cancer Institute, St. Luke’s Hospital, Division of Urology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Tor Vergata University of Rome,
Abstract
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,
Abstract
A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.Org: Memorial Sloan Kettering Cancer Center, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku, Seoul National University Hospital, Hospital Quirón Madrid, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.Org: St. John of God Hospital Subiaco, Queen Elizabeth Hospital, University of Adelaide, Woodville, St. George Hospital,
Abstract
Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Epworth Healthcare, Western Health, Walter and Eliza Hall Institute of Medical Research, University of Melbourne,
Abstract
Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.Org: Austin Health and Peter MacCallum Cancer Centre, Melbourne, Australia, Garvan Institute of Medical Research, Sydney, Australia, The Kinghorn Cancer Centre,
Abstract
CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906.Org: Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Chris O'Brien Lifehouse, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, Princess Alexandra Hospital & University of Queensland,